Amorfix Life Sciences Ltd. (Amorfix) is an early-stage product development company. The Company is engaged in developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS, to predict disease specific epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two technologies to identify very low levels of misfolded proteins in a biological sample: Epitope Protection and AMFIA, which is an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for Alzheimer�s disease (AD), and an method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD.